Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Rearrangements of T- and B-cell receptor (TCR and BCR) genes are useful markers for clonality assessment as well as for minimal residual disease (MRD) monitoring during the treatment of haematological malignancies.
|
31587259 |
2020 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The relative methylation level obtained during the follow-ups by MSP was compared to the MRD results obtained by the amplification of IG/TCR clonal rearrangements using the allele-specific quantitative-PCR (ASO-PCR) assay.
|
31486880 |
2019 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Minimal residual disease (MRD) measured by PCR of clonal IgH/TCR rearrangements predicts relapse in T-cell acute lymphoblastic leukemia (T-ALL) and serves as risk stratification tool.
|
30552401 |
2019 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The present study aimed to examine whether monoclonal immunoglobulin heavy chain (IGH) or T-cell receptor (TCR) gene rearrangement in cell-free DNA (cfDNA) may be used for minimal residual disease (MRD) monitoring in patients with acute myeloid leukemia (AML).
|
30008930 |
2018 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
An ASO-qPCR technique was then applied for 2.5-year monthly MRD quantification for detection of patient-specific Ig/TCR receptor rearrangements as a molecular target.
|
29392424 |
2018 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Comparing the results with standard MRD monitoring based on immunoglobulin/T-cell receptor (Ig/TCR) gene rearrangements and with quantification of <i>IKZF1</i> deletion, we observed very good correlation for the methods in a majority of patients; however, >20% of children (25% [8/32] with minor and 12.5% [1/8] with major-<i>BCR-ABL1</i> variants in the consecutive cohorts) had significantly (>1 log) higher levels of <i>BCR-ABL1</i> fusion than Ig/TCR rearrangements and/or <i>IKZF1</i> deletion.
|
28331056 |
2017 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Seventy-one patients were treated according to the GMALL 07/2003 protocol and evaluated for MRD in bone marrow by specific clonal rearrangements of Ig/TCR in BCR-ABL negative ALL or fusion gene transcript in BCR-ABL positive ALL.
|
25997106 |
2016 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Acute lymphoblastic leukemia (ALL) cells have unique rearranged immunoglobulin heavy chain (IgH), immunoglobulin light chain (IgK), and T-cell receptor (TCR) genes, which can be used as markers for clonality assay and evaluation of minimal residual disease.
|
24620952 |
2014 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
MRD status was assessed in 43 patients by the detection of major rearrangements in TCR and Ig and the presence of chimeric mRNA.
|
23388549 |
2013 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Minimal residual disease was detected by polymerase chain reaction (PCR) with homo/heteroduplex analysis using consensus primers to IgH and TCR genes.
|
21774746 |
2012 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Quantification of minimal residual disease (MRD) by real-time PCR directed to TCR and Ig gene rearrangements allows a refined evaluation of response in acute lymphoblastic leukemia (ALL).
|
22442346 |
2012 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
As expected, HTS of TCRB and TCRG identified MRD that was not detected by flow cytometry in a subset of cases (25 of 35 HTS compared with 13 of 35, respectively), which highlights the potential of this technology to define lower detection thresholds for MRD that could affect clinical treatment decisions.
|
22593176 |
2012 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This TCR-V(β)-R strategy is valuable in staging and evaluating MRD in patients with T-cell non-Hodgkin lymphoma.
|
22261447 |
2012 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Detection of minimal residual disease (MRD) during the treatment of acute lymphoblastic leukemia (ALL) by RQ-PCR analysis of clonal Ig/TCR rearrangements is used for risk group stratification in European treatment protocols.
|
21596436 |
2011 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements function as specific markers for minimal residual disease (MRD), which is one of the best predictors of outcome in childhood acute lymphoblastic leukemia (ALL).
|
20730889 |
2010 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TCR gene rearrangement is important in the diagnosis of clonality and used as markers to detect minimal residual disease in lymphoproliferative disorders.
|
21114900 |
2010 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This chapter provides all relevant background information and technical aspects for the complete laboratory process from detection of the clonal Ig/TCR gene rearrangements in ALL cells at diagnosis to the actual MRD measurements in clinical follow-up samples.
|
19277574 |
2009 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The convergence of Ig/TCR patterns in Polish and European patients indicates that the strategy for Ig/TCR target identification based on standard primers and protocols might be directly used for the construction of Polish standards and recommendations for MRD diagnostics.
|
19043668 |
2009 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Although quantitative detection of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements is currently considered to be the standard method, leukaemia fusion genes provide other possible targets for MRD follow-up, as already demonstrated in TEL/AML1-positive ALLs.
|
19158828 |
2009 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
In this study, we followed minimal residual disease (MRD) in eight children with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) using (i) flow cytometry (FCM), (ii) real-time quantitative PCR of IG/TCR gene rearrangements and (iii) RT-PCR detecting fusion gene transcripts.
|
19157547 |
2009 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We conclude that although Ig/TCR quantification is a reliable method for post transplant MRD detection, isolated positivities in Ig-based RQ-PCR systems at the time of intense B-cell regeneration must be viewed with caution to avoid the wrong indication of treatment.
|
18490915 |
2008 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We show that MRD quantitation using clonal Ig/TCR rearrangements successfully assesses the risk in pediatric ALL patients undergoing allogeneic HSCT.
|
16521130 |
2007 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The detected TCR gene rearrangements can also be used as PCR targets for monitoring of minimal residual disease.
|
17170730 |
2007 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
|
17287850 |
2007 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Results show that both aGVHD and minimal residual disease (MRD) eradication did significantly affect TCR gamma/delta profile.
|
16249028 |
2006 |